Data availability No datasets were generated or analysed during the current study
Semaglutide activates GLP-1 receptors throughout the body, triggering weight loss and metabolic changes that occasionally produce muscle cramping in the legs, shoulders, or abdomen
Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al
Ozempic (semaglutide) is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus, administered as a once-weekly subcutaneous injection
An FDA-approved drug comes with a defined indication, a validated dosing protocol, a safety surveillance system, and manufacturer accountability
However, patients with significantly impaired kidney function, recurrent urinary tract infections, a history of euglycemic DKA, or who are on multiple diabetes medications that lower blood sugar should discuss the combination carefully with their provider before starting